Back to top
more

H Lundbeck A/S (HLUYY)

(Delayed Data from OTC)

$43.01 USD

43.01
1,318

+0.33 (0.77%)

Updated May 3, 2019 03:45 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Strength Seen in H Lundbeck AS (HLUYY): Can Its 11.2% Jump Turn into More Strength?

by Zacks Equity Research

H Lundbeck AS (HLUYY) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

H Lundbeck AS (HLUYY) Surges 12.5%: Is This an Indication of Further Gains?

by Zacks Equity Research

H Lundbeck AS (HLUYY) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Are These Medical Stocks Undervalued Right Now?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Are These Medical Stocks Undervalued Right Now?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

H. Lundbeck (HLUYY): Strong Industry, Solid Earnings Estimate Revisions

by Zacks Equity Research

H. Lundbeck (HLUYY) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

USANA Health (USNA) Soars to 52-Week High, Time to Cash Out?

by Zacks Equity Research

USANA Health (USNA) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Sanofi's MAA for Pompe Disease Candidate Gets EMA's Acceptance

by Zacks Equity Research

The European Medicines Agency accepts for review Sanofi's (SNY) marketing authorization application for avalglucosidase alfa as a long-term enzyme replacement therapy for treating Pompe disease.

Bayer's Drug Meets Primary Endpoint in Renal Outcomes Study

by Zacks Equity Research

Bayer's (BAYRY) investigational candidate, finerenone, meets primary endpoint in the phase III FIDELIO_DKD study in patients with CKD and T2D.

AstraZeneca's sNDA for Brilinta Gets FDA's Priority Review

by Zacks Equity Research

The FDA accepts AstraZeneca's (AZN) sNDA for Brilinta under a Priority Review to lower subsequent stroke in patients who experienced an acute ischemic stroke or transient ischemic attack.

H. Lundbeck (HLUYY): Strong Industry, Solid Earnings Estimate Revisions

by Zacks Equity Research

H. Lundbeck (HLUYY) has seen solid earnings estimate revision activity over the past two months, and belongs to a strong industry as well.

Is H. Lundbeck (HLUYY) a Profitable Pick for Value Investors?

by Zacks Equity Research

Let's see if H. Lundbeck (HLUYY) stock is a good choice for value-oriented investors right now from multiple angles.

Merck's Keytruda Clinches CHMP Nod for Difficult Lung Cancer

by Zacks Equity Research

Merck (MRK) secures a positive verdict from the Committee for Medicinal Products for Human Use to approve Keytruda's combo therapy for first-line treatment of a difficult lung cancer population.

Novo Nordisk (NVO) Q4 Earnings Miss Estimates, Revenues Beat

by Zacks Equity Research

Novo Nordisk (NVO) fourth-quarter 2018 results mainly benefit from strong performance by Ozempic.

Lilly (LLY) Hits 52-Week High, Can the Run Continue?

by Zacks Equity Research

Lilly (LLY) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Sanofi's (SNY) Influenza Vaccine Gets FDA Approval for Kids

by Zacks Equity Research

Sanofi's (SNY) influenza vaccine, Fluzone Quadrivalent (0.5mL dose), gains an FDA nod for treating children in six to 35-month age group.

AbbVie's Imbruvica Fails in Phase III Pancreatic Cancer Study

by Zacks Equity Research

AbbVie's (ABBV) Imbruvica falls short of meeting the primary endpoint of PFS or OS benefit in a phase III study that probed its combo usage in first-line metastatic pancreatic cancer.

Lilly Stops Lartruvo Promotion as Confirmatory Study Fails

by Zacks Equity Research

Eli Lilly's (LLY) Lartruvo combo is unable to demonstrate the clinical benefit for the primary endpoint of OS rate in a phase III study related to treating patients with metastatic soft tissue sarcoma.

Pfizer's Xtandi Gets FDA Nod for Expanded Patient Population

by Zacks Equity Research

FDA approves Pfizer's (PFE) sNDA to expand the label of Xtandi to include the non-metastatic prostate cancer patient population.

    Amgen Resubmits BLA to FDA for Osteoporosis Candidate Evenity

    by Zacks Equity Research

    Amgen Inc. (AMGN) and its partner UCB announce the resubmission of the BLA to the FDA for Evenity to treat osteoporosis in postmenopausal women and in men at increased risk of fracture.

      J&J (JNJ) to Pay $4.69 Billion to Some Women in Talc Lawsuit

      by Zacks Equity Research

      Johnson & Johnson (JNJ) has been ordered to pay $4.69 billion in damages to 22 families who alleged that the company's baby powder contained asbestos that caused them to develop ovarian cancer.

        Will J&J's (JNJ) Pharma Segment Strength Drive Q2 Earnings?

        by Zacks Equity Research

        The positive trend seen in J&J's (JNJ) pharma segment sales in the past three quarters is likely to continue in Q2

          Madhu Goel headshot

          3 Buy-Rated Large Cap Pharma Stocks to Boost Health in July

          by Madhu Goel

          We take a look at the three large cap pharma stocks that might be best bargains for the month of July.

            Lilly's (LLY) Taltz Positive in Ankylosing Spondylitis Study

            by Zacks Equity Research

            Lilly (LLY) posts positive top-line results from a second phase III study on Taltz for the treatment of Ankylosing Spondylitis (AS).

              Pfizer's Leukemia Candidate Gets Priority Review From FDA

              by Zacks Equity Research

              The FDA grants a priority review to Pfizer's (PFE) NDA for leukemia candidate glasdegib for the first-line treatment of acute myeloid leukemia (AML) in combination with chemotherapy.

                AbbVie's (ABBV) Imbruvica sNDA Gets Priority Review From FDA

                by Zacks Equity Research

                The FDA grants a priority review to AbbVie's (ABBV) lymphoma drug Imbruvica sNDA, for the treatment of Waldenstr??m's macroglobulinemia (WM).